Free tool
FAERS Monitor: Sinuva
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209310 or its brand name (Sinuva, Mometasone Furoate). Reports on generic versions are filed under their own applications.
Reports
10,454
Serious
7,256
69% of reports
Hospitalization
3,151
Death reported
489
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,001
- drug ineffective925
- headache916
- asthma904
- off label use780
- cough750
- fatigue677
- pruritus640
- gastrooesophageal reflux disease593
- nausea563
- wheezing562
- hypersensitivity556
- pain539
- pneumonia512
- rash453
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 57 |
| 2005 | 56 |
| 2006 | 56 |
| 2007 | 91 |
| 2008 | 150 |
| 2009 | 122 |
| 2010 | 145 |
| 2011 | 143 |
| 2012 | 145 |
| 2013 | 96 |
| 2014 | 108 |
| 2015 | 168 |
| 2016 | 299 |
| 2017 | 326 |
| 2018 | 764 |
| 2019 | 769 |
| 2020 | 734 |
| 2021 | 982 |
| 2022 | 1,219 |
| 2023 | 1,225 |
| 2024 | 1,019 |
| 2025 | 1,028 |
| 2026 | 752 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,705 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wheezingSignal | 562 | 19.2 | 17.7 | 9,635 |
| asthmaSignal | 904 | 16.2 | 15.2 | 12,857 |
| gastrooesophageal reflux diseaseSignal | 593 | 14.9 | 13.8 | 7,662 |
| hypersensitivitySignal | 556 | 6.0 | 5.6 | 2,348 |
| coughSignal | 750 | 5.4 | 5.0 | 2,708 |
| dyspnoeaSignal | 1,001 | 3.6 | 3.4 | 1,890 |
| pruritusSignal | 640 | 3.4 | 3.1 | 1,073 |
| pneumoniaSignal | 512 | 3.2 | 2.9 | 776 |
| headacheSignal | 916 | 2.9 | 2.8 | 1,207 |
| rashSignal | 453 | 2.1 | 1.9 | 262 |
| off label use | 780 | 1.8 | 1.7 | 284 |
| pain | 539 | 1.8 | 1.6 | 184 |
| fatigue | 677 | 1.8 | 1.6 | 225 |
| nausea | 563 | 1.4 | 1.3 | 76 |
| drug ineffective | 925 | 1.4 | 1.3 | 118 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.